Literature DB >> 19679072

Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy.

Isabella Palazzolo1, Conor Stack, Lingling Kong, Antonio Musaro, Hiroaki Adachi, Masahisa Katsuno, Gen Sobue, J Paul Taylor, Charlotte J Sumner, Kenneth H Fischbeck, Maria Pennuto.   

Abstract

Expansion of a polyglutamine tract in the androgen receptor (AR) causes spinal and bulbar muscular atrophy (SBMA). We previously showed that Akt-mediated phosphorylation of AR reduces ligand binding and attenuates the mutant AR toxicity. Here, we show that in culture insulin-like growth factor 1 (IGF-1) reduces AR aggregation and increases AR clearance via the ubiquitin-proteasome system through phosphorylation of AR by Akt. In vivo, SBMA transgenic mice overexpressing a muscle-specific isoform of IGF-1 selectively in skeletal muscle show evidence of increased Akt activation and AR phosphorylation and decreased AR aggregation. Augmentation of IGF-1/Akt signaling rescues behavioral and histopathological abnormalities, extends the life span, and reduces both muscle and spinal cord pathology of SBMA mice. This study establishes IGF-1/Akt-mediated inactivation of mutant AR as a strategy to counteract disease in vivo and demonstrates that skeletal muscle is a viable target tissue for therapeutic intervention in SBMA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679072      PMCID: PMC2735765          DOI: 10.1016/j.neuron.2009.07.019

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  50 in total

1.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy.

Authors:  A R La Spada; E M Wilson; D B Lubahn; A E Harding; K H Fischbeck
Journal:  Nature       Date:  1991-07-04       Impact factor: 49.962

2.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

3.  Localized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.

Authors:  Gloria Bonuccelli; Federica Sotgia; Franco Capozza; Elisabetta Gazzerro; Carlo Minetti; Michael P Lisanti
Journal:  Cell Cycle       Date:  2007-05-27       Impact factor: 4.534

4.  In vivo suppression of polyglutamine neurotoxicity by C-terminus of Hsp70-interacting protein (CHIP) supports an aggregation model of pathogenesis.

Authors:  Aislinn J Williams; Tina M Knutson; Veronica F Colomer Gould; Henry L Paulson
Journal:  Neurobiol Dis       Date:  2008-11-08       Impact factor: 5.996

Review 5.  Behavioral phenotyping strategies for mutant mice.

Authors:  Jacqueline N Crawley
Journal:  Neuron       Date:  2008-03-27       Impact factor: 17.173

6.  Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy.

Authors:  Haruhiko Banno; Masahisa Katsuno; Keisuke Suzuki; Yu Takeuchi; Motoshi Kawashima; Noriaki Suga; Motoko Takamori; Mizuki Ito; Tomohiko Nakamura; Koji Matsuo; Shinichi Yamada; Yumiko Oki; Hiroaki Adachi; Makoto Minamiyama; Masahiro Waza; Naoki Atsuta; Hirohisa Watanabe; Yasushi Fujimoto; Tsutomu Nakashima; Fumiaki Tanaka; Manabu Doyu; Gen Sobue
Journal:  Ann Neurol       Date:  2009-02       Impact factor: 10.422

7.  Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

Authors:  Brian K Kaspar; Jerònia Lladó; Nushin Sherkat; Jeffrey D Rothstein; Fred H Gage
Journal:  Science       Date:  2003-08-08       Impact factor: 47.728

Review 8.  PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?

Authors:  M A Lawlor; D R Alessi
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

9.  Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors.

Authors:  P Caroni; P Grandes
Journal:  J Cell Biol       Date:  1990-04       Impact factor: 10.539

10.  Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females.

Authors:  Gianni Sorarù; Carla D'Ascenzo; Alberto Polo; Arianna Palmieri; Linda Baggio; Lodovica Vergani; Cinzia Gellera; Giuseppe Moretto; Elena Pegoraro; Corrado Angelini
Journal:  J Neurol Sci       Date:  2007-09-12       Impact factor: 3.181

View more
  110 in total

Review 1.  Developing treatment for spinal and bulbar muscular atrophy.

Authors:  Kenneth H Fischbeck
Journal:  Prog Neurobiol       Date:  2012-06-02       Impact factor: 11.685

2.  SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA.

Authors:  Heather L Montie; Richard G Pestell; Diane E Merry
Journal:  J Neurosci       Date:  2011-11-30       Impact factor: 6.167

Review 3.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

4.  Contractile dysfunction in muscle may underlie androgen-dependent motor dysfunction in spinal bulbar muscular atrophy.

Authors:  Kentaro Oki; Katherine Halievski; Laura Vicente; Youfen Xu; Donald Zeolla; Jessica Poort; Masahisa Katsuno; Hiroaki Adachi; Gen Sobue; Robert W Wiseman; S Marc Breedlove; Cynthia L Jordan
Journal:  J Appl Physiol (1985)       Date:  2015-02-05

Review 5.  Genetic approaches to the treatment of inherited neuromuscular diseases.

Authors:  Bhavya Ravi; Anthony Antonellis; Charlotte J Sumner; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

6.  Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice.

Authors:  Li-Kai Tsai; Chien-Lin Chen; Chen-Hung Ting; Sue Lin-Chao; Wuh-Liang Hwu; James C Dodge; Marco A Passini; Seng H Cheng
Journal:  Mol Ther       Date:  2014-05-12       Impact factor: 11.454

Review 7.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

8.  Serine 421 regulates mutant huntingtin toxicity and clearance in mice.

Authors:  Ian H Kratter; Hengameh Zahed; Alice Lau; Andrey S Tsvetkov; Aaron C Daub; Kurt F Weiberth; Xiaofeng Gu; Frédéric Saudou; Sandrine Humbert; X William Yang; Alex Osmand; Joan S Steffan; Eliezer Masliah; Steven Finkbeiner
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

Review 9.  In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy.

Authors:  Maria Pennuto; Manuela Basso
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

Review 10.  Clinical Trials in Spinal and Bulbar Muscular Atrophy-Past, Present, and Future.

Authors:  Patrick Weydt; Anna Sagnelli; Angela Rosenbohm; Pietro Fratta; Pierre-François Pradat; Albert C Ludolph; Davide Pareyson
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.